During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same manufacturer may choose to market the drug under different proprietary names in various countries. Furthermore, multiple manufacturers may assign distinct proprietary names to the same drug. In such instances, nonproprietary names prove more useful, as they enable the identification of the drug based on its pharmacological class. Healthcare professionals often prefer nonproprietary names when prescribing medication, as doing so can save money and facilitate communication. To ensure the drug's consistent quality and therapeutic efficacy, the U.S. Food and Drug Administration (FDA) has established bioavailability standards. Information pertaining to therapeutic equivalence evaluations is compiled in an official publication for reference purposes.
